<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680560</url>
  </required_header>
  <id_info>
    <org_study_id>ATTCK-34-01</org_study_id>
    <nct_id>NCT03680560</nct_id>
  </id_info>
  <brief_title>Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers</brief_title>
  <official_title>A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cogent Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cogent Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, multi-center study to assess safety and determine the&#xD;
      recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination&#xD;
      with trastuzumab, following lymphodepleting chemotherapy in subjects with HER2-positive&#xD;
      advanced malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business Reasons&#xD;
  </why_stopped>
  <start_date type="Actual">March 13, 2019</start_date>
  <completion_date type="Actual">March 12, 2020</completion_date>
  <primary_completion_date type="Actual">March 12, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of ACTR T cell product with trastuzumab as assessed by committee review of dose limiting toxicities (DLTs), incidence and severity of adverse events (AEs) and clinically significant abnormalities of laboratory values</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of recommended phase 2 dose (RP2D) regimen</measure>
    <time_frame>42 days</time_frame>
    <description>Review of DLTs, maximum tolerated dose (MTD), incidence and severity of AEs and clinically significant abnormalities of laboratory values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity as measured by overall response rate (ORR) per iRECIST</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity as measured best overall response (BOR)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity as measured by duration of response (DOR)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity as measured by progression-free survival (PFS)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity as measured by overall survival (OS)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of persistence of ACTR as measured by flow cytometry</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of persistence of ACTR as measured by quantitative polymerase chain reaction (qPCR)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of ACTR phenotype and function as measured by flow cytometry</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of induction of inflammatory markers and cytokines/chemokines after ACTR T cell product administration</measure>
    <time_frame>52 weeks</time_frame>
    <description>Levels of inflammatory markers, cytokines/chemokines in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trastuzumab pharmacokinetics (PK)</measure>
    <time_frame>52 weeks</time_frame>
    <description>trastuzumab serum concentration, Area Under the Curve (AUC), trough levels</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Solid Tumor</condition>
  <condition>HER-2 Protein Overexpression</condition>
  <arm_group>
    <arm_group_label>ACTR T cell product in combination with trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACTR T Cell Product</intervention_name>
    <description>Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087)</description>
    <arm_group_label>ACTR T cell product in combination with trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>monoclonal antibody targeting HER2</description>
    <arm_group_label>ACTR T cell product in combination with trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent obtained prior to study procedures&#xD;
&#xD;
          -  Histologically-confirmed Her2 positive advanced solid tumor malignancy with documented&#xD;
             disease progression during or immediately following the immediate prior therapy, or&#xD;
             within 6 months of completing adjuvant therapy for subjects with breast cancer&#xD;
&#xD;
          -  Subjects must have previously received adequate standard therapy for treatment of&#xD;
             their malignancy&#xD;
&#xD;
               -  For those with metastatic breast cancer, must have received HER2-directed therapy&#xD;
                  including trastuzumab, pertuzumab and ado-trastuzumab in any breast cancer&#xD;
                  disease setting&#xD;
&#xD;
               -  For those with advanced gastric cancer, adequate prior treatment with&#xD;
                  HER2-directed chemotherapy is required&#xD;
&#xD;
          -  At least 1 measurable lesion by iRECIST&#xD;
&#xD;
          -  Able to provide fresh tumor biopsy or archived block specimen taken since time of most&#xD;
             recent anti-HER2 mAb-directed therapy&#xD;
&#xD;
          -  ECOG of 0 or 1&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  LVEF ≥ 50% by MUGA or ECHO&#xD;
&#xD;
          -  Absolute neutrophil (ANC) count ≥ 1500/ µL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/µL&#xD;
&#xD;
          -  Hemoglobin ≥ 9g/dL&#xD;
&#xD;
          -  Estimated GFR &gt;30mL/min/1.73m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  glioblastoma multiforme or other primary CNS tumors are excluded&#xD;
&#xD;
          -  clinically significant cardiac disease&#xD;
&#xD;
          -  clinically significant active infection&#xD;
&#xD;
          -  clinical history, prior diagnosis, or overt evidence of autoimmune disease&#xD;
&#xD;
          -  current use of more than 5mg/day of prednisone (or an equivalent glucocorticoid)&#xD;
&#xD;
          -  Prior treatment as follows:&#xD;
&#xD;
               -  prior cumulative doxorubicin dose greater than or equal to 300 mg/m^2 or&#xD;
                  equivalent&#xD;
&#xD;
               -  chemotherapy within 2 weeks of enrollment&#xD;
&#xD;
               -  external beam radiation within 2 weeks of enrollment (28 days if CNS-directed&#xD;
                  therapy)&#xD;
&#xD;
               -  any monoclonal antibody (mAb) or other protein therapeutic containing Fc-domains&#xD;
                  within 4 weeks of enrollment&#xD;
&#xD;
               -  pertuzumab within 4 months of enrollment&#xD;
&#xD;
               -  Experimental agents within 3 half-lives or 28 days prior to enrollment, whichever&#xD;
                  is shorter&#xD;
&#xD;
               -  allogeneic hematopoietic stem cell transplant (HSCT)&#xD;
&#xD;
               -  prior infusion of a genetically modified therapy&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glen Weiss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cogent Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Smilow Cancer Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami University Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute/Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.unumrx.com/</url>
    <description>Sponsor Website</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2</keyword>
  <keyword>ACTR</keyword>
  <keyword>ACTR087</keyword>
  <keyword>ACTR707</keyword>
  <keyword>T cell</keyword>
  <keyword>T cell product</keyword>
  <keyword>adoptive T cells</keyword>
  <keyword>gene therapy</keyword>
  <keyword>breast cancer</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>gastro esophageal cancer</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>solid tumor</keyword>
  <keyword>adenoid cystic carcinoma</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

